Sodium Phosphate Injection USP offers 15mM, 45mM, and 150mM single‑dose vials for hypophosphatemia treatment worldwide.

• Indicated as a phosphorus source for IV fluids, preventing or treating hypophosphatemia in non‑oral patients today.
• Used to customize parenteral nutrition when standard electrolyte solutions fail to meet specific patient requirements.
• 2025 US sales reached $67 million, reflecting strong demand across hospitals and emerging markets globally today.